logo
Product categories

EbookNice.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link.  https://ebooknice.com/page/post?id=faq


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookNice Team

(Ebook) Proteasome Inhibitors in Cancer Therapy by Julian Adams ISBN 9781588292506, 9781592597949, 1588292509, 1592597947

  • SKU: EBN-1386518
Zoomable Image
$ 32 $ 40 (-20%)

Status:

Available

0.0

0 reviews
Instant download (eBook) Proteasome Inhibitors in Cancer Therapy after payment.
Authors:Julian Adams
Pages:330 pages.
Year:2004
Editon:1
Publisher:Humana Press
Language:english
File Size:7.19 MB
Format:pdf
ISBNS:9781588292506, 9781592597949, 1588292509, 1592597947
Categories: Ebooks

Product desciption

(Ebook) Proteasome Inhibitors in Cancer Therapy by Julian Adams ISBN 9781588292506, 9781592597949, 1588292509, 1592597947

A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcadeв„ў) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
*Free conversion of into popular formats such as PDF, DOCX, DOC, AZW, EPUB, and MOBI after payment.

Related Products